Phase I Study of Alternating Doublets of Topotecan/Carboplatin and Paclitaxel/Carboplatin in Patients with Newly Diagnosed, Advanced Ovarian Cancer

This publication has 14 references indexed in Scilit:

• Cancer Statistics, 2001
  CA: A Cancer Journal for Clinicians, 2001
• Phase II Feasibility Study of Sequential Couplets of Cisplatin/Topotecan Followed by Paclitaxel/Cisplatin as Primary Treatment for Advanced Epithelial Ovarian Cancer: A National Cancer Institute of Canada Clinical Trials Group Study
  Journal of Clinical Oncology, 2000
• Exploratory Phase III Study of Paclitaxel and Cisplatin Versus Paclitaxel and Carboplatin in Advanced Ovarian Cancer
  Journal of Clinical Oncology, 2000
• Randomized Intergroup Trial of Cisplatin-Paclitaxel Versus Cisplatin-Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results
  JNCI Journal of the National Cancer Institute, 2000
• Phase I and Pharmacologic Study of the Combination of Paclitaxel, Cisplatin, and Topotecan Administered Intravenously Every 21 Days as First-Line Therapy in Patients With Advanced Ovarian Cancer
  Journal of Clinical Oncology, 1999
• ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer
  The Lancet, 1998
• Topotecan in Platinum- and Paclitaxel-Resistant Ovarian Cancer
  Gynecologic Oncology, 1997
• Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
  New England Journal of Medicine, 1996
• Consensus Panel Says Benefits of Screening Women for Ovarian Cancer Currently Unproven
  JAMA, 1994
• Treatment of Ovarian Carcinoma: Possibilities for Progress
  New England Journal of Medicine, 1972